-
1
-
-
84886430163
-
Novel anti-angiogenic therapies in ovarian cancer
-
Kaye S, Brown R, Gabra H, Gore M, editor. New York: Springer
-
Hasan J, Jayson G. Novel anti-angiogenic therapies in ovarian cancer. In: Kaye S, Brown R, Gabra H, Gore M, editor. Emerging therapeutic targets in ovarian cacner. New York: Springer; 2011. p. 51-72.
-
(2011)
Emerging Therapeutic Targets in Ovarian Cacner
, pp. 51-72
-
-
Hasan, J.1
Jayson, G.2
-
2
-
-
0037862963
-
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2. 2 trial
-
Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106.
-
(2003)
Lancet
, vol.361
, pp. 2099-2106
-
-
Parmar, M.K.1
Ledermann, J.A.2
Colombo, N.3
Du Bois, A.4
Delaloye, J.F.5
Kristensen, G.B.6
-
3
-
-
0038576158
-
The power and the promise of DNA methylation markers
-
Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 253-266
-
-
Laird, P.W.1
-
4
-
-
84871923658
-
Epigenetics makes its mark on women-specific cancers-an opportunity to redefine oncological approaches?
-
Widschwendter M, Jones A, Teschendorff AE. Epigenetics makes its mark on women-specific cancers-an opportunity to redefine oncological approaches? Gynecol Oncol 2013;128:134-43.
-
(2013)
Gynecol Oncol
, vol.128
, pp. 134-143
-
-
Widschwendter, M.1
Jones, A.2
Teschendorff, A.E.3
-
5
-
-
84869876903
-
Detection of cancer-specific epigenomic changes in biofluids: Powerful tools in biomarker discovery and application
-
Nogueira da Costa A, Herceg Z. Detection of cancer-specific epigenomic changes in biofluids: powerful tools in biomarker discovery and application. Mol Oncol 2012;6:704-15.
-
(2012)
Mol Oncol
, vol.6
, pp. 704-715
-
-
Nogueira Da Costa, A.1
Herceg, Z.2
-
7
-
-
84855466019
-
A phase 3 trial of bevacizumab in ovarian cancer
-
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96.
-
(2011)
N Engl J Med
, vol.365
, pp. 2484-2496
-
-
Perren, T.J.1
Swart, A.M.2
Pfisterer, J.3
Ledermann, J.A.4
Pujade-Lauraine, E.5
Kristensen, G.6
-
8
-
-
84855425106
-
Incorporation of bevacizumab in the primary treatment of ovarian cancer
-
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.
-
(2011)
N Engl J Med
, vol.365
, pp. 2473-2483
-
-
Burger, R.A.1
Brady, M.F.2
Bookman, M.A.3
Fleming, G.F.4
Monk, B.J.5
Huang, H.6
-
9
-
-
79955477996
-
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
-
O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 2011;121:269-72.
-
(2011)
Gynecol Oncol
, vol.121
, pp. 269-272
-
-
O'Malley, D.M.1
Richardson, D.L.2
Rheaume, P.S.3
Salani, R.4
Eisenhauer, E.L.5
McCann, G.A.6
-
10
-
-
84861736119
-
OCEANS: A randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
-
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30:2039-45
-
(2012)
J Clin Oncol
, vol.30
, pp. 2039-2045
-
-
Aghajanian, C.1
Blank, S.V.2
Goff, B.A.3
Judson, P.L.4
Teneriello, M.G.5
Husain, A.6
-
11
-
-
79959218200
-
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival
-
Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, et al. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 2011;17:4052-62.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4052-4062
-
-
Dai, W.1
Teodoridis, J.M.2
Zeller, C.3
Graham, J.4
Hersey, J.5
Flanagan, J.M.6
-
12
-
-
0033535612
-
A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer
-
Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999;18:2335-41.
-
(1999)
Oncogene
, vol.18
, pp. 2335-2341
-
-
Strathdee, G.1
Mackean, M.J.2
Illand, M.3
Brown, R.4
-
13
-
-
33644830699
-
Reporting recommendations for tumor marker prognostic studies
-
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
-
(2005)
J Clin Oncol
, vol.23
, pp. 9067-9072
-
-
McShane, L.M.1
Altman, D.G.2
Sauerbrei, W.3
Taube, S.E.4
Gion, M.5
Clark, G.M.6
-
14
-
-
0031981857
-
Dependence of McrBC cleavage on distance between recognition elements
-
Stewart FJ, Raleigh EA. Dependence of McrBC cleavage on distance between recognition elements. Biol Chem 1998;379:611-6.
-
(1998)
Biol Chem
, vol.379
, pp. 611-616
-
-
Stewart, F.J.1
Raleigh, E.A.2
-
15
-
-
0026634757
-
McrBC: A multisubunit GTP-dependent restriction endonuclease
-
Sutherland E, Coe L, Raleigh EA. McrBC: a multisubunit GTP-dependent restriction endonuclease. J Mol Biol 1992;225:327-48.
-
(1992)
J Mol Biol
, vol.225
, pp. 327-348
-
-
Sutherland, E.1
Coe, L.2
Raleigh, E.A.3
-
16
-
-
79959838081
-
Integrated genomic analyses of ovarian carcinoma
-
Cancer Genome Atlas Research N
-
Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
-
(2011)
Nature
, vol.474
, pp. 609-615
-
-
-
17
-
-
0001677717
-
Controlling the false discovery rate: A practical and powerful approach to multiple testing
-
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 1995;57:289-300.
-
(1995)
J R Stat Soc ser B (Methodological)
, vol.57
, pp. 289-300
-
-
Benjamini, Y.1
Hochberg, Y.2
-
18
-
-
62449153727
-
Ovarian cancer: Pathology, biology, and disease models
-
Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, et al. Ovarian cancer: pathology, biology, and disease models. Front Biosci 2009;14:2089-102.
-
(2009)
Front Biosci
, vol.14
, pp. 2089-2102
-
-
Rosen, D.G.1
Yang, G.2
Liu, G.3
Mercado-Uribe, I.4
Chang, B.5
Xiao, X.S.6
-
19
-
-
0034213974
-
Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy
-
Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9.
-
(2000)
Cancer
, vol.88
, pp. 2584-2589
-
-
Sugiyama, T.1
Kamura, T.2
Kigawa, J.3
Terakawa, N.4
Kikuchi, Y.5
Kita, T.6
-
20
-
-
0036498788
-
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
-
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1248-1259
-
-
Bristow, R.E.1
Tomacruz, R.S.2
Armstrong, D.K.3
Trimble, E.L.4
Montz, F.J.5
-
21
-
-
33847065486
-
The epigenomics of cancer
-
Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128: 683-92.
-
(2007)
Cell
, vol.128
, pp. 683-692
-
-
Jones, P.A.1
Baylin, S.B.2
-
22
-
-
84861153520
-
Global methylation profiling for risk prediction of prostate cancer
-
Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, et al. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 2012;18:2882-95.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2882-2895
-
-
Mahapatra, S.1
Klee, E.W.2
Young, C.Y.3
Sun, Z.4
Jimenez, R.E.5
Klee, G.G.6
-
23
-
-
67650401865
-
DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage
-
Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 2008;1:47.
-
(2008)
BMC Med Genomics
, vol.1
, pp. 47
-
-
Watts, G.S.1
Futscher, B.W.2
Holtan, N.3
Degeest, K.4
Domann, F.E.5
Rose, S.L.6
-
24
-
-
3042774430
-
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients
-
Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004;10: 4420-6.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 4420-4426
-
-
Gifford, G.1
Paul, J.2
Vasey, P.A.3
Kaye, S.B.4
Brown, R.5
-
25
-
-
84867743287
-
Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
-
Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012;31:4567-76.
-
(2012)
Oncogene
, vol.31
, pp. 4567-4576
-
-
Zeller, C.1
Dai, W.2
Steele, N.L.3
Siddiq, A.4
Walley, A.J.5
Wilhelm-Benartzi, C.S.6
-
26
-
-
78649537524
-
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
-
Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172-83.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1172-1183
-
-
Jubb, A.M.1
Harris, A.L.2
-
27
-
-
84865141645
-
VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression
-
Cao Y, E G, Wang E, Pal K, Dutta SK, Bar-Sagi D, et al. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res 2012;72: 3912-8.
-
(2012)
Cancer Res
, vol.72
, pp. 3912-3918
-
-
Cao, Y.1
Eo, G.2
Wang, E.3
Pal, K.4
Dutta, S.K.5
Bar-Sagi, D.6
-
28
-
-
84856684201
-
Complicated life, complicated VEGF-B
-
Li X, Kumar A, Zhang F, Lee C, Tang Z. Complicated life, complicated VEGF-B. Trends Mol Med 2012;18:119-27.
-
(2012)
Trends Mol Med
, vol.18
, pp. 119-127
-
-
Li, X.1
Kumar, A.2
Zhang, F.3
Lee, C.4
Tang, Z.5
-
29
-
-
78649655419
-
Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis
-
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE 2010;5:e14109.
-
(2010)
PLoS ONE
, vol.5
-
-
Albrecht, I.1
Kopfstein, L.2
Strittmatter, K.3
Schomber, T.4
Falkevall, A.5
Hagberg, C.E.6
-
30
-
-
40549090548
-
VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats
-
Li Y, Zhang F, Nagai N, Tang Z, Zhang S, Scotney P, et al. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 2008;118:913-23.
-
(2008)
J Clin Invest
, vol.118
, pp. 913-923
-
-
Li, Y.1
Zhang, F.2
Nagai, N.3
Tang, Z.4
Zhang, S.5
Scotney, P.6
-
31
-
-
60549100360
-
Integral role of transcription factor 8 in the negative regulation of tumor angiogenesis
-
Inuzuka T, Tsuda M, Tanaka S, Kawaguchi H, Higashi Y, Ohba Y. Integral role of transcription factor 8 in the negative regulation of tumor angiogenesis. Cancer Res 2009;69:1678-84.
-
(2009)
Cancer Res
, vol.69
, pp. 1678-1684
-
-
Inuzuka, T.1
Tsuda, M.2
Tanaka, S.3
Kawaguchi, H.4
Higashi, Y.5
Ohba, Y.6
-
32
-
-
77956945067
-
BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma
-
Ibrahim N, He L, Leong CO, Xing D, Karlan BY, Swisher EM, et al. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res 2010;70:7155-65.
-
(2010)
Cancer Res
, vol.70
, pp. 7155-7165
-
-
Ibrahim, N.1
He, L.2
Leong, C.O.3
Xing, D.4
Karlan, B.Y.5
Swisher, E.M.6
-
33
-
-
0035129906
-
From angiogenesis to lymphangiogenesis
-
Plate K. From angiogenesis to lymphangiogenesis. Nat Med 2001;7: 151-2.
-
(2001)
Nat Med
, vol.7
, pp. 151-152
-
-
Plate, K.1
-
34
-
-
84873267168
-
Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer
-
Cheng D, Liang B, Li Y. Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS ONE 2013;8:e55309.
-
(2013)
PLoS ONE
, vol.8
-
-
Cheng, D.1
Liang, B.2
Li, Y.3
-
35
-
-
20944436359
-
Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas
-
Ueda M, Hung YC, Terai Y, Kanda K, Kanemura M, Futakuchi H, et al. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res 2005;11:3225-32.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3225-3232
-
-
Ueda, M.1
Hung, Y.C.2
Terai, Y.3
Kanda, K.4
Kanemura, M.5
Futakuchi, H.6
-
36
-
-
69249103708
-
Transcriptional regulation of vascular endothelial growth factor C by oxidative and thermal stress is mediated by lens epithelium-derived growth factor/p75
-
Cohen B, Addadi Y, Sapoznik S, Meir G, Kalchenko V, Harmelin A, et al. Transcriptional regulation of vascular endothelial growth factor C by oxidative and thermal stress is mediated by lens epithelium-derived growth factor/p75. Neoplasia 2009;11:921-33.
-
(2009)
Neoplasia
, vol.11
, pp. 921-933
-
-
Cohen, B.1
Addadi, Y.2
Sapoznik, S.3
Meir, G.4
Kalchenko, V.5
Harmelin, A.6
|